The ARTS-HF trial revealed that finerenone had comparable efficacy to eplerenone in reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and showed a lower likelihood of adverse events, such as all-cause mortality, cardiovascular hospitalization, or emergency presentation for worsening HF [24]. This evidence concerns the gene NPPB and hydrops fetalis.